Skip Navigation
Skip to contents

대한심장학회 : 전문인

대한심장학회 통합검색

자료실

이달의 증례

HOME > 자료실 > 이달의 증례
  • 글자크기 크게
  • 글자크기 작게
  • 컨텐츠영역 프린트
이달의 kcj Hot Article / 2026년 7월
One Versus Two Months Anticoagulation After Catheter Ablation for Atrial Fibrillation in Patients Who Were Not Indicated for Long-Term OAC: A Pilot Randomized Controlled Trial (The REDUCIBLE Trial)
저자 Nilar Aung, MB, BS, PhD,1 Soyoon Park, MD,2 Soohyun Kim, MD,3 Young Choi, MD,2 Yong-Seog Oh, MD, PhD,2 Seunghee Baek, PhD,4 and Sung-Hwan Kim, MD, PhD5
소속 1Cardiac Medical Unit, No. 1. Defense Services General Hospital, Yangon, Myanmar. 2Division of Cardiology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. 3Division of Cardiology, Department of Internal Medicine, Incheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Incheon, Korea. 4Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. 5Department of Cardiology, Asan Medical Center, Seoul, Korea.

Background and Objectives

Even low-risk atrial fibrillation (AF) patients usually continue anticoagulant therapy for several months after the procedure. However, there is no solid evidence supporting this practice. The REDUCIBLE trial is designed to compare the outcomes of conventional 2- versus 1-month oral anticoagulant (OAC) therapy following successful catheter ablation (CA) in men with a CHA2DS2-VASc score of ≤1 and women with ≤2, where long-term OAC is not recommended.

Methods

In this pilot study, patients undergoing CA for drug-refractory paroxysmal AF were randomly divided into 2 groups. One group received OAC for 1 month, whereas the other received it for 2 months. The primary outcome was the incidence of stroke and systemic embolism within 1 year after ablation.

Results

A total of 220 patients were enrolled and randomly assigned to 2 groups. Baseline characteristics were similar between the groups. The AF recurrence-free survival (RFS) rate was similar (76.9% vs. 77.7%, p=0.98). During the blanking period, AF RFS was also similar (92.5% vs. 92.9%, p=0.98). No ischemic stroke or systemic embolism occurred in either group during 1-year follow-up. One patient in the 1-month group experienced a minor bleeding event when anticoagulants were not taken (7 months after ablation).

Conclusions

This study found that a single month of OAC post-ablation did not significantly elevate the risk of stroke or systemic embolism in low-risk patients. Nonetheless, a larger sample size would be necessary to achieve the statistical power for definitive conclusions. Future larger prospective clinical trials are needed to address this question comprehensively.

Trial Registration

ClinicalTrials.gov Identifier: NCT03573037
첨부파일1 kcj-56-606-abf001.jpg kcj-56-606-abf001.jpg (다운 2회)
목록

위로 이동

대한심장학회
서울특별시 마포구 마포대로 109 롯데캐슬프레지던트 101동 1704호 (우: 04146)
  • Tel : 02-3275-5258
  • Fax : 02-3275-5259
  • E-mail : herz1@circulation.or.kr
  • 사업자등록번호 : 106-82-31184
  • 대표자 : 강석민

  • Copyright© The Korean Society of Cardiology
네이버 블로그 facebook insta
학회소개
학술 행사
학회지(KCJ)
심장학 최신지견 따라잡기
진료지침
자료실
회원공간
공지사항

닫기